Kymera Therapeutics (KYMR) Current Assets (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Current Assets data on file, last reported at $677.4 million in Q1 2026.

• Current Assets for Q1 2026 came in at $677.4 million, up 35.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $677.4 million (up 35.23% YoY), and the FY2025 annual result was $871.2 million, up 70.74% from the prior year.
• Current Assets slipped to $677.4 million in Q1 2026 per KYMR's latest filing, from $871.2 million in the prior quarter.
• Over five years, Current Assets peaked at $871.2 million in Q4 2025 and troughed at $375.7 million in Q3 2023.
• A 5-year average of $516.1 million and a median of $501.0 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2025: Current Assets declined 23.95% in 2023, then jumped 70.74% in 2025.
• A 5-year view of Current Assets shows it stood at $419.4 million in 2022, then fell by 3.36% to $405.3 million in 2023, then climbed by 25.89% to $510.3 million in 2024, then jumped by 70.74% to $871.2 million in 2025, then retreated by 22.24% to $677.4 million in 2026.
• Business Quant data shows KYMR's Current Assets at $677.4 million in Q1 2026, $871.2 million in Q4 2025, and $528.3 million in Q3 2025.